Form 4: Merck Director Acquires Phantom Stock Under Deferred Plan

Merck & Co. Director Christine E. Seidman acquired 67.5451 phantom stock units under a deferred compensation plan, to be settled in cash upon termination of service.

Summary

• Christine E. Seidman, a Director at Merck & Co., Inc. (MRK), acquired 67.5451 phantom stock units.
• The transaction occurred on March 31, 2026, as part of a pre-arranged plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Each phantom stock unit has an underlying value equivalent to one share of common stock, priced at $120.29.
• These units will be settled 100% in cash upon Seidman's termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation.
• Following this acquisition, Seidman beneficially owns 19,238.3277 phantom stock units, which includes units from dividend reinvestment transactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting a director's continued participation in the company's long-term incentive plan and alignment with shareholder interests, without indicating any immediate operational changes.

Positives

• The acquisition of phantom stock by a director indicates continued alignment of interests with shareholders, as the value is tied to the company's common stock performance.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, suggesting a pre-scheduled, non-discretionary acquisition.

Risks

• The value of the phantom stock units is tied to Merck's common stock price, meaning a decline in share price would reduce the ultimate cash settlement value for the director.

Future Outlook

The phantom stock units are designed to be settled in cash upon the reporting person's termination of service, indicating a long-term incentive structure tied to future company performance.

Industry Context

StockSavvy.ai notes that phantom stock plans are a common form of executive and director compensation in the pharmaceutical industry, aligning long-term incentives with company performance without immediate equity dilution.

Comparison to Industry Standards

• Phantom stock plans are a standard compensation tool for directors across various industries, including large pharmaceutical companies like Pfizer, Johnson & Johnson, and Novartis, which often use similar deferred compensation mechanisms to retain talent and align interests.
• The specific terms, such as cash settlement and linkage to common stock value, are typical for such arrangements within global benchmarks for executive compensation.

Stakeholder Impact

• Shareholders: The acquisition of phantom stock by a director aligns their financial interests with those of shareholders, as the value is tied to the company's stock performance.

Next Steps

• The phantom stock units will be settled in cash upon Christine E. Seidman's termination of service, according to a pre-elected distribution schedule.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled acquisition of phantom stock by a director as part of a compensation plan. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It merely confirms ongoing director compensation practices.

Keywords

Merck, MRK, Form 4, Insider Trading, Phantom Stock, Director Compensation, Deferred Compensation, Equity Compensation, Christine Seidman